Baylor College of Medicine: Neuroblastoma trials

The registry lists 14 Neuroblastoma studies with Baylor College of Medicine as lead sponsor. 2 are open to participants now and 2 have results posted.

Phase 1 12Phase 2 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or NeuroblastomaRecruitingNCT07211737Phase 1
• GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With NeuroblastomaRecruitingNCT03294954Phase 1
• High-Risk Neuroblastoma Chemotherapy Without G-CSFCompletedNCT02786719Not applicableResults posted
• Protracted Etoposide During Induction Therapy for High Risk NeuroblastomaCompletedNCT00578864Phase 2Results posted
• C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)Active, not recruitingNCT03635632Phase 1
• 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMAWithdrawnNCT02439788Phase 1
• iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and NeuroblastomaActive, not recruitingNCT01953900Phase 1
• 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNCT01822652Phase 1
• Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALLCompletedNCT01713439Phase 1
• Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk NeuroblastomaActive, not recruitingNCT01192555Phase 1/2
• A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor CellsCompletedNCT00703222Phase 1/2
• Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone InvolvementCompletedNCT00206388Phase 1
• Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma PatientsCompletedNCT00085930Phase 1
• Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory NeuroblastomaCompletedNCT00062855Phase 1